A clinical-stage biotech developing psychedelic-inspired drugs for brain disorders, like MM120 for anxiety and ADHD, and MM402 for autism.
No revenue yet; it burns cash, with net losses of USD -0.18B in 2025 and USD -0.11B in 2024, funded by investors.
Its drug candidates are novel and patented, but big pharma like Pfizer and AbbVie could outspend and outcompete in trials. Moat is weak because no approved product or clear advantage exists yet.
